tiprankstipranks
Trending News
More News >
Summit Therapeutics PLC (SMMT)
:SMMT
US Market

Summit Therapeutics (SMMT) Stock Forecast & Price Target

Compare
1,834 Followers
See the Price Targets and Ratings of:

SMMT Analyst Ratings

Moderate Buy
12Ratings
Moderate Buy
8 Buy
3 Hold
1 Sell
Based on 12 analysts giving stock ratings to
Summit
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SMMT Stock 12 Month Forecast

Average Price Target

$42.49
▲(138.44% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Summit Therapeutics in the last 3 months. The average price target is $42.49 with a high forecast of $131.90 and a low forecast of $18.00. The average price target represents a 138.44% change from the last price of $17.82.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"$16","45":"$45","74":"$74","103":"$103","132":"$132"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":131.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$131.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42.49,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$42.49</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,45,74,103,132],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.26,26.07846153846154,34.89692307692307,43.715384615384615,52.533846153846156,61.35230769230769,70.17076923076922,78.98923076923077,87.8076923076923,96.62615384615384,105.44461538461537,114.26307692307692,123.08153846153846,{"y":131.9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.26,19.200769230769232,21.141538461538463,23.082307692307694,25.023076923076925,26.963846153846156,28.904615384615386,30.845384615384617,32.78615384615385,34.72692307692308,36.667692307692306,38.60846153846154,40.549230769230775,{"y":42.49,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.26,17.31692307692308,17.373846153846156,17.430769230769233,17.48769230769231,17.544615384615387,17.601538461538464,17.658461538461538,17.715384615384615,17.77230769230769,17.82923076923077,17.886153846153846,17.943076923076923,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.49,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.5,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.8,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.67,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.72,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.07,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.84,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.49,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.91,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.26,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$131.90Average Price Target$42.49Lowest Price Target$18.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on SMMT
Barclays
Barclays
$16$18
Hold
1.01%
Upside
Upgraded
12/17/25
Summit Therapeutics (SMMT) was upgraded to a Hold Rating at Barclays
Citi
$40$131.9
Buy
640.18%
Upside
Reiterated
12/02/25
Citi Keeps Their Buy Rating on Summit Therapeutics (SMMT)
Wolfe Research Analyst forecast on SMMT
Unknown Analyst
Wolfe Research
Not Ranked
Wolfe Research
Hold
Initiated
11/17/25
Summit Therapeutics initiated with a Peer Perform at Wolfe ResearchSummit Therapeutics initiated with a Peer Perform at Wolfe Research
TD Cowen
Buy
Reiterated
11/10/25
Positive Outlook for Summit Therapeutics Amid Strategic Clinical Advancements
Clear Street Analyst forecast on SMMT
Clear Street
Clear Street
$32
Buy
79.57%
Upside
Reiterated
11/10/25
Clear Street Remains a Buy on Summit Therapeutics (SMMT)
UBS
$30$33
Buy
85.19%
Upside
Reiterated
11/10/25
Summit Therapeutics (SMMT) Gets a Buy from UBS
Truist Financial Analyst forecast on SMMT
Truist Financial
Truist Financial
Buy
Reiterated
11/10/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbCellera Biologics (NASDAQ: ABCL), ANI Pharmaceuticals (NASDAQ: ANIP) and Summit Therapeutics (NASDAQ: SMMT)
Leerink Partners Analyst forecast on SMMT
Leerink Partners
Leerink Partners
Sell
Reiterated
10/22/25
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT) and Viatris (NASDAQ: VTRS)
Wells Fargo Analyst forecast on SMMT
Wells Fargo
Wells Fargo
$30
Buy
68.35%
Upside
Reiterated
10/21/25
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT), IDEAYA Biosciences (NASDAQ: IDYA) and Rani Therapeutics Holdings (NASDAQ: RANI)
H.C. Wainwright Analyst forecast on SMMT
H.C. Wainwright
H.C. Wainwright
$50$40
Buy
124.47%
Upside
Reiterated
10/21/25
Summit Therapeutics price target lowered to $40 from $50 at H.C. WainwrightSummit Therapeutics price target lowered to $40 from $50 at H.C. Wainwright
Evercore ISI Analyst forecast on SMMT
Evercore ISI
Evercore ISI
$34
Buy
90.80%
Upside
Reiterated
10/20/25
Evercore ISI Reaffirms Their Buy Rating on Summit Therapeutics (SMMT)
Piper Sandler Analyst forecast on SMMT
Piper Sandler
Piper Sandler
$21
Hold
17.85%
Upside
Reiterated
10/20/25
Piper Sandler Reaffirms Their Hold Rating on Summit Therapeutics (SMMT)
Roth MKM Analyst forecast on SMMT
Unknown Analyst
Roth MKM
Not Ranked
Roth MKM
$13
Sell
-27.05%
Downside
Initiated
09/17/25
Summit Therapeutics (SMMT) Gets a Sell from Roth MKM
Citizens JMP Analyst forecast on SMMT
Citizens JMP
Citizens JMP
$40
Buy
124.47%
Upside
Reiterated
09/08/25
Citizens JMP Remains a Buy on Summit Therapeutics (SMMT)
Guggenheim Analyst forecast on SMMT
Guggenheim
Guggenheim
$40
Buy
124.47%
Upside
Initiated
09/03/25
Summit Therapeutics initiated with a Buy at GuggenheimSummit Therapeutics initiated with a Buy at Guggenheim
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on SMMT
Barclays
Barclays
$16$18
Hold
1.01%
Upside
Upgraded
12/17/25
Summit Therapeutics (SMMT) was upgraded to a Hold Rating at Barclays
Citi
$40$131.9
Buy
640.18%
Upside
Reiterated
12/02/25
Citi Keeps Their Buy Rating on Summit Therapeutics (SMMT)
Wolfe Research Analyst forecast on SMMT
Unknown Analyst
Wolfe Research
Not Ranked
Wolfe Research
Hold
Initiated
11/17/25
Summit Therapeutics initiated with a Peer Perform at Wolfe ResearchSummit Therapeutics initiated with a Peer Perform at Wolfe Research
TD Cowen
Buy
Reiterated
11/10/25
Positive Outlook for Summit Therapeutics Amid Strategic Clinical Advancements
Clear Street Analyst forecast on SMMT
Clear Street
Clear Street
$32
Buy
79.57%
Upside
Reiterated
11/10/25
Clear Street Remains a Buy on Summit Therapeutics (SMMT)
UBS
$30$33
Buy
85.19%
Upside
Reiterated
11/10/25
Summit Therapeutics (SMMT) Gets a Buy from UBS
Truist Financial Analyst forecast on SMMT
Truist Financial
Truist Financial
Buy
Reiterated
11/10/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbCellera Biologics (NASDAQ: ABCL), ANI Pharmaceuticals (NASDAQ: ANIP) and Summit Therapeutics (NASDAQ: SMMT)
Leerink Partners Analyst forecast on SMMT
Leerink Partners
Leerink Partners
Sell
Reiterated
10/22/25
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT) and Viatris (NASDAQ: VTRS)
Wells Fargo Analyst forecast on SMMT
Wells Fargo
Wells Fargo
$30
Buy
68.35%
Upside
Reiterated
10/21/25
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT), IDEAYA Biosciences (NASDAQ: IDYA) and Rani Therapeutics Holdings (NASDAQ: RANI)
H.C. Wainwright Analyst forecast on SMMT
H.C. Wainwright
H.C. Wainwright
$50$40
Buy
124.47%
Upside
Reiterated
10/21/25
Summit Therapeutics price target lowered to $40 from $50 at H.C. WainwrightSummit Therapeutics price target lowered to $40 from $50 at H.C. Wainwright
Evercore ISI Analyst forecast on SMMT
Evercore ISI
Evercore ISI
$34
Buy
90.80%
Upside
Reiterated
10/20/25
Evercore ISI Reaffirms Their Buy Rating on Summit Therapeutics (SMMT)
Piper Sandler Analyst forecast on SMMT
Piper Sandler
Piper Sandler
$21
Hold
17.85%
Upside
Reiterated
10/20/25
Piper Sandler Reaffirms Their Hold Rating on Summit Therapeutics (SMMT)
Roth MKM Analyst forecast on SMMT
Unknown Analyst
Roth MKM
Not Ranked
Roth MKM
$13
Sell
-27.05%
Downside
Initiated
09/17/25
Summit Therapeutics (SMMT) Gets a Sell from Roth MKM
Citizens JMP Analyst forecast on SMMT
Citizens JMP
Citizens JMP
$40
Buy
124.47%
Upside
Reiterated
09/08/25
Citizens JMP Remains a Buy on Summit Therapeutics (SMMT)
Guggenheim Analyst forecast on SMMT
Guggenheim
Guggenheim
$40
Buy
124.47%
Upside
Initiated
09/03/25
Summit Therapeutics initiated with a Buy at GuggenheimSummit Therapeutics initiated with a Buy at Guggenheim
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Summit Therapeutics

1 Month
xxx
Success Rate
6/9 ratings generated profit
67%
Average Return
-0.44%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of -0.44% per trade.
3 Months
xxx
Success Rate
5/7 ratings generated profit
71%
Average Return
+8.59%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +8.59% per trade.
1 Year
Bradley CaninoGuggenheim
Success Rate
5/7 ratings generated profit
71%
Average Return
+230.26%
initiated a buy rating 4 months ago
Copying Bradley Canino's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +230.26% per trade.
2 Years
xxx
Success Rate
4/7 ratings generated profit
57%
Average Return
+148.81%
initiated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 57.14% of your transactions generating a profit, with an average return of +148.81% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SMMT Analyst Recommendation Trends

Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
11
13
18
17
10
Buy
17
14
16
10
7
Hold
1
1
2
2
3
Sell
3
5
5
5
1
Strong Sell
1
2
3
2
1
total
33
35
44
36
22
In the current month, SMMT has received 17 Buy Ratings, 3 Hold Ratings, and 2 Sell Ratings. SMMT average Analyst price target in the past 3 months is 42.49.
Each month's total comprises the sum of three months' worth of ratings.

SMMT Financial Forecast

SMMT Earnings Forecast

Next quarter’s earnings estimate for SMMT is -$0.24 with a range of -$0.33 to -$0.12. The previous quarter’s EPS was -$0.31. SMMT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year SMMT has Performed in-line its overall industry.
Next quarter’s earnings estimate for SMMT is -$0.24 with a range of -$0.33 to -$0.12. The previous quarter’s EPS was -$0.31. SMMT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year SMMT has Performed in-line its overall industry.

SMMT Sales Forecast

Next quarter’s sales forecast for SMMT is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. SMMT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year SMMT has Performed in-line its overall industry.
Next quarter’s sales forecast for SMMT is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. SMMT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year SMMT has Performed in-line its overall industry.

SMMT Stock Forecast FAQ

What is SMMT’s average 12-month price target, according to analysts?
Based on analyst ratings, Summit Therapeutics PLC’s 12-month average price target is 42.49.
    What is SMMT’s upside potential, based on the analysts’ average price target?
    Summit Therapeutics PLC has 138.44% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is SMMT a Buy, Sell or Hold?
          Summit Therapeutics PLC has a consensus rating of Moderate Buy which is based on 8 buy ratings, 3 hold ratings and 1 sell ratings.
            What is Summit Therapeutics PLC’s price target?
            The average price target for Summit Therapeutics PLC is 42.49. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $131.90 ,the lowest forecast is $18.00. The average price target represents 138.44% Increase from the current price of $17.82.
              What do analysts say about Summit Therapeutics PLC?
              Summit Therapeutics PLC’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of SMMT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.